Nektar TherapeuticsNKTRNASDAQ
Loading
Cash Flow Under PressureContracting
Percentile Rank29
Studio
Year-over-Year Change

Cash generated from core business operations

Latest
$-208.51M
↓ 47% vs avg
Percentile
P29
Within normal range
Streak
1 yr
Consecutive declineContracting
Average
$-141.47M
Historical baseline
PeriodValueYoY Change
TTM$-208.51M-18.7%
2024$-175.71M+8.8%
2023$-192.61M+36.6%
2022$-304.01M+26.3%
2021$-412.66M-31.7%
2020$-313.29M+4.7%
2019$-328.68M-145.8%
2018$718.21M+993.1%
2017$-80.41M+31.3%
2016$-117.02M-